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Abstract
Background: NF-B is a survival signaling transcription factor complex involved in the malignant phenotype of
many cancers, including squamous cell carcinomas (SCC). The citrus coumarin, auraptene (AUR), and the ethno-
medicinal ginger (Alpinia galanga) phenylpropanoid, 1’-acetoxychavicol acetate (ACA), were previously shown to
suppress 12-O-tetradecanoylphorbol-13-acetate (TPA) induced mouse skin tumor promotion. The goal of the
present study was to determine whether AUR and ACA are effective either alone or in combination with all-trans
retinoic acid (ATRA) for suppressing SCC tumor growth.
Methods: We first determined the effects of orally administered ACA (100 mg/kg bw) and AUR (200 mg/kg bw)
on lipopolysaccharide (LPS)-induced NF-B activation in NF-B-RE-luc (Oslo) luciferase reporter mice. Dietary
administration of AUR and ACA ± ATRA was next evaluated in a xenograft mouse model. Female SCID/bg mice
were fed diets containing the experimental compounds, injected with 1 × 10
6 SRB12-p9 cells s.c., palpated and
weighed twice a week for 28 days following injection.
Results: Both ACA and AUR suppressed LPS-induced NF-B activation in the report mice. In the xenograft model,
AUR (1000 ppm) and ACA (500 ppm) modestly suppressed tumor volume. However, in combination with ATRA at
5, 10, and 30 ppm, ACA 500 ppm significantly inhibited tumor volume by 56%, 62%, and 98%, respectively. The
effect of ATRA alone was 37%, 33%, and 93% inhibition, respectively. AUR 1000 ppm and ATRA 10 ppm were not
very effective when administered alone, but when combined, strongly suppressed tumor volume by 84%.
Conclusions: Citrus AUR may synergize the tumor suppressive effects of ATRA, while ACA may prolong the
inhibitory effects of ATRA. Further studies will be necessary to determine whether these combinations may be
useful in the control of human SCC.
Background
Non-melanoma skin cancer (NMSC) is the most com-
mon cancer in the U.S., with over a million new cases
of the two most common forms, squamous cell carci-
noma (SCC) and basal cell carcinoma (BCC), anticipated
annually [1]. The more clinically aggressive form is SCC
of the skin [2], which has been increasing in incidence
since the 1960 s at annual rates from 4% to as much as
10% in recent years. Better control of advanced skin
SCC is clearly necessary, and will be helped by improv-
ing our understanding of the molecular basis for skin
carcinogenesis and of the action of chemopreventive
drugs.
Nuclear factor B( N F - B) is activated during inflam-
mation and carcinogenesis [3]. Lipopolysaccharide
(LPS), interleukin-1b, hydrogen peroxide, and tumor
necrosis factor activate NF-B signaling through phos-
phorylation of its inhibitor IBa. This leads to degrada-
tion of IBa, phosphorylation of the p65 NF-B
subunit, and translocation of p65, along with the p50
subunit, to the nucleus. There they form a DNA binding
complex and activate transcription of specific genes
involved in proliferation (cyclin D1, c-myc, COX-2),
angiogenesis (vascular endothelial growth factor-VEGF),
antiapoptosis (survivin, TRAF1, IAP1, BclXL, FLIP) and
invasion (matrix metalloproteinase 9, ICAM-1) [4].
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nent of traditional Thai condiments, present in the
seeds (15000 ppm) and rhizomes (27300 ppm) of the
ethnomedicinal plant Languas galanga Stuntz (Zingiber-
aceae) [5]. In the skin model, pre-treatment of mice
with ACA prior to TPA treatment in 7,12-dimethylbenz
[a]anthracene (DMBA)-initiated mice suppressed skin
tumor promotion [6]. Recently it was found that ACA
blocked TNF-a induced activation of NF-B indirectly
through IB [7]. In this regard, ACA inhibited TNF-a-
induced phosphorylation and degradation of IBa,s u g -
gesting that it inhibits the IBa kinase, IKK. Auraptene
(AUR) is a geranyloxy-coumarin obtained from citrus
fruits [8], the aromatic plant Zanthoxylum schinifolium
[9] and the fruits of Paliurus ramosissimus [10]. AUR is
also known to suppress skin tumor promotion [8], in
addition to its many other chemopreventive effects.
AUR suppresses superoxide generation indirectly, most
likely through inhibition of the multi-component
NADPH oxidase system [8]. AUR, possessing anti-
inflammatory activities [11] also suppresses ulcerative
colitis and ulcerative colitis induced colon cancer
[12,13]. Consistent with these observations, AUR also
activated PPARg in adipocytes, which led to the
increased production of adiponection, which is known
to suppress the inflammatory process [14]. These varied
mechanisms and protective effects in rodent models of
cancer, combined with the low risk of toxicity [15], sug-
gest that AUR might be a good candidate for skin SCC
chemoprevention.
Retinoids are a class of chemical compounds, which
include active metabolites of vitamin A (retinol), as well
as a diverse array of synthetic derivatives. Retinoids have
been shown to modulate multiple cellular processes,
including proliferation, differentiation, homeostasis,
malignant transformation and apoptosis [16-18]. ATRA
has long been known as one of the most effective sup-
pressors of tumor formation in the 2-stage mouse skin
chemical carcinogenesis model [19,20]. We have
recently used this model to further explore the mechan-
ism of ATRA action and have demonstrated that ATRA
targets the B-Raf/Mek/Erk signaling pathway and this
activity coincides with its chemopreventive activity [21].
We have also shown recently that ATRA can suppress
Stat3 signaling in skin carcinogenesis, and that Stat3
activity lies downstream of the B-Raf/Mek/Erk pathway
[22]. It is interesting to note that many downstream sig-
naling effectors involved in malignancy are regulated by
both Stat3 and NF-B
We hypothesized that suppression of both B-Raf/
Mek/Erk/Stat3 and NF-B signaling through combined
administration of ATRA and ACA/AUR, may exert a
stronger anti-tumor effect than either agent alone.
Methods
Cell culture
The human skin SCC cell line SRB12-p9 was derived by
single cell cloning from SRB12 cells (a gift from
Dr. Reuben Lotan, Department of Thoracic Head and
Neck Medical Oncology, University of Texas M.D. Ander-
son Cancer Center). Cells were cultured in a humidified
atmosphere at 5% CO2, in Dulbecco’s Modified Eagle’s
Media-F12 supplemented with 10% fetal bovine serum.
Severe combined immunodeficient (SCID) beige mice
SCID/bg mice were housed sterile cages in a tempera-
ture and humidity controlled AAALAC facility under a
normal 12 hour light/dark cycle. All procedures were
approved by LSUHSC Institutional Animal Care and
Use Committee in accordance with NIH guidelines. The
mice were allowed access to autoclaved food and water
ad libitum.
NF-B-RE-luc (Oslo) mice
All mice were allowed food and water ad libitum and
were housed according to institutional and NIH guide-
lines. Mice were purchased from the Xenogen Corpora-
tion (Alameda, California) and are bred and genotyped
in our breeding colony. NF-B-RE-luc is a light produ-
cing animal model that carries a transgene containing 3
NF-B response elements from the Ig light chain pro-
moter and modified firefly luciferase cDNA (Promega
pGL-3) [23]. The reporter is expressed under basal con-
ditions in the lymph node (neck), thymus (thoracic
region), and Peyer’s patches (abdominal region). Various
inflammatory stimuli induce the reporter, such as LPS,
TNF-a, and arthritis, which makes it suitable for the
study of transcriptional regulation of NF-B. Male and
female mice (n = 3-4) were pre-treated with ACA (100
mg/kg bw), AUR (200 mg/kg bw) or vehicle (0.2 mL
corn oil/25 g bw) once a day for 4 consecutive days. At
30 min after the last pretreatment, mice were injected
with LPS (2.7 mg/kg bw). Mice were imaged on an IVIS
100 Imaging System at 30 min after the 3
rd pre-treat-
ment dose as a pre-screen to ensure that the pre-treat-
ments themselves did not activate NF-B. Mice were
imaged again at 3 h and 24 h after LPS treatment. Mice
were injected with 2.5 mg D-luciferin substrate, along
with ketamine/xylazine anesthetic, 15 minutes prior to
each imaging. Luminescence intensity was quantified
using Living Image (R) 3.0 software (Caliper Life
Sciences, Inc., Hopkinton, MA).
Xenograft Model
Groups of 5-8 female SCID/bg mice (6-12 weeks of age)
each were fed control diets or diets containing ATRA
(5, 10, 30 ppm), ACA (500 ppm) or AUR (1000 ppm) or
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inoculation and for the duration of the study. Test diets
were administered prior to the injection of tumor cells
to be a chemoprevention protocol. In humans, this
might be applicable to individuals who have been trea-
ted for a primary tumor, but are susceptible to the
development of subsequent tumors. This could be a
window of opportunity for chemoprevention. Mice were
shaved (2 days prior to injection), then injected with 1 ×
10
6 SRB12-p9 cells suspended in sterile PBS, s.c., pal-
pated and weighed twice a week for 25-28 days follow-
ing injection. Tumors were measured using digital
calipers and tumor volume (mm
3) was calculated using
the following formula, based on the assumption of a
near-spherical tumor shape: V = ((l + w)/4)
3 *1 . 3 3*P I ,
where l =l e n g t h ,w = width. The studies were con-
ducted at different times, so the timing was kept to a
25-28 day window for consistency. All mice in a particu-
lar study were euthanized on the same day so that com-
parisons could be made.
microPET imaging
Tumor bearing mice were investigated by non-invasive
imaging using a R4 microPET scanner (Siemens Medical
Solutions USA, Inc., Knoxville, TN). In brief, the system
operates in three dimensions and is composed of 6144
lutetium oxyorthosilicate crystal (LSO) detector ele-
ments, with a 7.8 cm axial and a 10 cm transaxial field-
of-view. The [18F]-3’-fluoro-3’-deoxy-L-thymidine ([18F]
FLT) radiotracer, a pyrimidine nucleoside analogue, has
been validated as a promising PET radiopharmaceutical
for monitoring tumor proliferation as well as response
to therapy [24]. The [18F]FLT was synthesized using a
3-N-Boc-5’-O-dimethoxytrityl-3’-O-nosyl-thymidine pre-
cursor according to published method of Eisenhut et al.
[25]. No-carrier-added [18F]FLT was administered intra-
venously by tail vein injection into experimental animals
at a dose of 300 mCi/mouse. Sixty minutes after injec-
tion, the animals were anesthetized, positioned in the
field of view of the scanner, and imaged for 15 minutes.
Subsequently, the microPET images were reconstructed
using an iterative reconstruction technique.
Glutathione S-transferase (GST) and NAD(P)H quinone
oxidoreductase (NQO) activities
Liver cytosolic GST activities were assayed spectropho-
tometrically (Shimadzu, Columbia, MD, kinetic mode)
using two different substrates [26]. First, liver cytosol
enriched fractions were prepared by differential centrifu-
gation as previously described [27]. Protein concentra-
tions were estimated using the Bradford method with
BSA as a standard [28]. Aliquots of cytosolic samples
were incubated with either 1 mM 1,2-dichloro-4-
nitrobenzene (DCNB), 5 mM GSH in 0.1 M
KH2PO4 buffer, pH 7.5; or with 1 mM 1-chloro-
2,4-dinitrobenzene (CDNB), 1 mM GSH, in
0.1 M KH2PO4 buffer, pH 6.5. Changes in absor-
bances were assessed at 340 nm (CDNB) or 345 nm
(DCNB), and enzyme activities were calculated using
extinction coefficients of 9.6 nM
-1/cm
-1 and 8.5 nM
-1/
cm
-1, respectively [29]. Liver cytosolic NQO activity was
assayed spectrophotometrically (kinetic mode) at 600
nm using 2,6-dichloroindophenol (1.25 mM) as a sub-





For NF-B and GST data, differences between groups
were compared using ANOVA followed by post-hoc
analysis with Fisher’s PLSD test and/or Tukey’st e s t .
Group comparisons are shown in the figure and table
legends. Descriptive statistics of body weight and tumor
volume were presented as means and least squared
means along with standard deviation and sample size
for a particular sub-group. Analysis of variance method
was used to compare the body weight and tumor
volume among groups (ACA, AUR and ATRA). Subse-
quently, the multiple comparison using Dunnett method
was made among the group (all other group compares
to control group). To perform the non-parametric data
analysis, the body weight and tumor volume were
ranked first and then similar analysis were performed as
described above. A linear trend test was performed to
assess the effect of ATRA dosage of 0, 5, 10, and 30
with/without ACA on the body weight and tumor
volume at particular days (13, 15, 20, and 22) after treat-
ment. Only these days have the same measurement for
the dosage of ATRA, the number of mice in the control
dosage level (0) were combination of two separated
experiment in this study (n = 13), the number of mice
a r e8 ,8 ,a n d5f o rd o s el e v e lo f5 ,1 0a n d3 0 .A l lp -
values, ≤ 0.05 were considered statistically significant.
All statistical data analysis was performed by using SAS
system 9.2 (SAS Inc, Gary, NC).
Results
ACA and AUR suppressed LPS-induced NF-B activation
in NF-B-RE-luc (Oslo) mice
Many phytochemicals suppress NF-B activation, so we
used a simple in vivo method using NF-B-RE-luc (Oslo)
to first determine whether ACA and AUR also pos-
sessed this inhibitory activity. Male and female mice
(n = 3-4) were pre-treated with ACA (100 mg/kg bw),
AUR (200 mg/kg bw) or vehicle (0.2 mL corn oil/25 g
bw) once a day for 4 consecutive days. On day 3, mice
were imaged as a pre-screen to ensure that ACA and
AUR did not activate the NF-Br e p o r t e r .O nd a y4 ,
30 min after the last pretreatment, mice were injected
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LPS treatment, as described in materials and methods.
Mice dosed with LPS expressed a significant increase in
NF-B luciferase at 3 h after LPS (Figures 1, 2). Both
ACA and AUR significantly inhibited NF-B luciferase
expression by 65% and 76%, respectively at 3 h after
LPS (Figure 2). There was very little luciferase expres-
sion at the pre-screen time point, confirming that the
pre-treatments did not activate NF-B. By 24 h, the
expression of luciferase declined and there were no sig-
nificant differences in any of the treatment groups.
ACA and ATRA suppression of skin SCC tumor growth: A
potentially beneficial combination
Previous data generated by our groups and others sug-
g e s t st h a tA T R Aa n dA C As u p p r e s sS t a t 3a n dN F - B
activation, respectively [7,22]. As both pathways have
been shown to be important in the development of var-
ious cancers including skin SCC, we hypothesized that
the simultaneous suppression of each pathway using
ATRA + ACA would be more effective than using either
agent alone at suppressing SCC growth. To address this
hypothesis, female SCID/bg mice were inoculated with 1
×1 0
6 SRB12-p9 cells and weighed and their tumors
were measure by digital calipers over the course of 25
days. Groups of 5-8 mice each were fed control diets or
diets containing ATRA (5, 10, and 30 ppm), ACA (500
ppm), or ATRA + ACA, starting 1 week prior to tumor
cell inoculation and for the duration of the study. The
dose of ACA was selected based on its activity in pre-
vious dietary studies [31-34]. Tumor volume increased
Figure 1 ACA and AUR suppress LPS-induced NF-B activation in NF-B-RE-luc (Oslo) mice. Picture depicts live animal imaging of
luciferase.
Figure 2 Quantitation of luminescence activity in the NF-B
study. Figures represent means ± SE (n = 3-4). * Significantly
different from control at the same time-point (p ≤ 0.05) (ANOVA
followed by Tukey’s test).
Kleiner-Hancock et al. BMC Cancer 2010, 10:394
http://www.biomedcentral.com/1471-2407/10/394
Page 4 of 10rapidly at day 15 to day 25 after inoculation in the con-
trol diet groups, reaching a maximum of 650-875 mm
3.
ACA had a marginally significant effect on tumor
volume between days 18-22 (Figures 3A, B) and [Addi-
tional file 1: Supplemental Tables S1, S2]. Dietary ATRA
(5 ppm) modestly suppressed tumor volume but not sig-
nificantly [Additional file 1: Supplemental Tables S1,
S2]. Comparing both parametric and non-parametric
analyses, the combination of 5 ppm ATRA and ACA in
the diet significantly inhibited tumor volume starting at
11 days and continuing throughout the study, ranging
from 56-76% inhibition [Additional file 1: Supplemental
Tables S1, S2]. 10 ppm ATRA modestly inhibited tumor
volume from 45-58% starting at day 11 up to day 22,
but its effects were marginally significant - significant
for a few days [Additional file 1: Supplemental Tables
S1, S2]. The combination of 10 ppm ATRA and ACA
significantly suppressed tumor volume by 50-67% start-
ing at day 11 to day 25, again comparing both
parametric and non-parametric analyses [Additional file
1: Supplemental Tables S1, S2]. In the 30 ppm ATRA
experiment, ACA did not exhibit any significant effects
on its own, although there was a 51% inhibition of
tumor volume at day 23 that was not statistically signifi-
cant. A lower number of subjects (5 mice instead of 7-
8) in this experiment likely contributed to this lack of
statistical significance, compared to the 5 and 10 ppm
ATRA studies. However, 30 ppm ATRA strongly sup-
pressed tumor volume by 70-93% from day 9 to day 23,
and the combination of ATRA 30 with ACA signifi-
cantly suppressed tumor volume from 89-98% (Figure
3C) and [Additional file 1: Supplemental Tables S1, S2].
Body weight analyses demonstrated a significant change
i nt h eA T R A5a n d3 0g r o u p s ,f o rm o s tt i m e - p o i n t s
[Additional file 1: Supplemental Table S3]. However,
dose-response analyses suggested that the effect was
independent of ACA [Additional file 1: Supplemental
Table S5]. Dose-response analyses of ATRA 5, 10, and
Figure 3 Effects of combinations of ACA/AUR ± ATRA on SRB12-p9 SCC tumor growth in SCID/bg mice. Groups of mice were fed diets
containing the following combinations [A] ACA 500 ppm ± ATRA 5 ppm (n = 7-8); [B] ACA 500 ppm ± ATRA 10 ppm (n = 7-8); [C] ACA 500
ppm ± ATRA 30 ppm (n = 5); and [D] AUR 1000 ppm ± ATRA 10 ppm (n = 5). Figures represent means ± S.E. Note that the first two
experiments (panels A & B) were conducted simultaneously, so the control and ACA groups are the same, but the two different doses of ATRA
± ACA were split into separate graphs for clarity.
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significance, suggesting the effect on tumor volume was
dependent on dose of ATRA [Additional file 1: Supple-
mental Table S4]. A linear trend analysis supported this
observation [Additional file 1: Supplemental Table S6].
Live animal imaging (FLT) of representative mice from
the 30 ppm ATRA combination study are shown in Fig-
ure 4. Sagittal sections through the tumor indicated that
the size of tumors visualized in live mice corresponded
with the values obtained from caliper measurements.
AUR and ATRA suppression of skin SCC tumor growth:
Another potentially beneficial combination
We next tested the AUR + ATRA combination in the
skin SCC xenograft model. As shown in Figure 3D and
[Additional file 1: Supplemental Table S7], treatment
with AUR (1000 ppm in the diet) alone did not reduce
tumor volume to a statistically significant level. 10 ppm
ATRA, as observed in the first set of studies, signifi-
cantly inhibited tumor volume by 49-87% starting at day
7 and continuing throughout the study (Figure 3D) and
Figure 4 Representative FLT-PET live animal imaging from the ACA 500 ± ATRA 30 study. Solid arrows marked with “T” point to the
tumors, and dashed arrows marked with “B” point to the urinary bladder, where the isotope is eliminated.
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nation of AUR + 10 ppm ATRA also significantly inhib-
ited tumor volume by 62-84% starting at day 7 and
continuing until day 25. At day 28, the combination of
ATRA + AUR suppressed tumor volume by 84%,
although the results were not statistically significant at
this date. Photos of tumors from representative mice
illustrate this strong combination effect (Figure 5). Sta-
tistical analysis of body weights showed a modest reduc-
tion in body weights in the ATRA treated groups
[Additional file 1: Supplemental Table S8].
Our laboratory and others have shown that one of the
chemopreventive activities of AUR is induction of phase
II detoxifying enzymes through activation of the Nrf-2/
antioxidant response element [35,36]. In the current
study, we also assessed whether the combination of
AUR and ATRA maintained this effect. As shown in
Table 1, AUR significantly induced GST activities using
DCNB as a substrate. No significant effects on NQO
activities or on GST activities using CDNB as a sub-
strate were observed. CDNB is a more general substrate
for GST activities [37], hence may have diluted out any
specific effects of AUR at the dietary exposure level in
the current study. Also, we have previously observed
that AUR is also not a very strong inducer of hepatic
NQO activity [35], so these results are not surprising.
However, it appeared that ATRA itself might have mod-
estly increased GST activity, and the combination of
AUR and ATRA did not afford any increase in activity
(using DCNB as a substrate) compared to ATRA alone,
and no statistically significant increase compared to the
vehicle control group. Thus ATRA may slightly inhibit
the GST inducing effect of AUR.
Discussion
Taken together, the current studies have demonstrated
that ACA and AUR suppressed LPS-induced activation
of NF-Bi nNF-B-Re-luc mice, and modestly inhibited
SRB12-p9 tumor growth in the xenograft model.
Although ATRA was fairly effective at doses as low as
Figure 5 Representative tumors from the Auraptene 1000 ± ATRA 10 study. Photographs were taken from duplicate mice in each group.
Lines were drawn around the tumor margins for clarity.
Table 1 Effects of dietary combinations of AUR and ATRA
on NQO1 and GST activities.
Diet NQO1 CDNB * 1000 DCNB * 1000
Control 3.17 ± 0.27 316 ± 36 14.9 ± 2.0
AUR 4.09 ± 0.30 371 ± 47 27.5 ± 0.7**
ATRA 3.01 ± 0.50 371 ± 34 18.3 ± 1.5
AUR + ATRA 4.27 ± 0.57 386 ± 16 18.8 ± 1.6
** Significantly different from control diet (p < 0.01, Tukey’st e s t )
Figures represent mean activities (μmol/min/mg protein) ± SE (n = 4-5).
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tained to the end of the study when combined with
either ACA or AUR. Although neither ACA nor AUR
possessed strong inhibitory effects on their own, these
data suggest that they may be useful in combination
with ATRA. This is particularly important because
ATRA is known to produce hypervitaminosis A-related
side effects, and if its dose can be limited and efficacy
improved by combining with naturally occurring dietary
agents, these combinations could be clinically useful.
However, diets containing ATRA led to a dose-related
decrease in body weights, which was not different when
combined with ACA or AUR.
Many other phytochemicals are known to suppress
NF-B activation [38]. Among these, several are related
to the Zingiberaceae family, including gingerol and cur-
cumin. These agents have been known to suppress
many types of cancer, including that of skin. Taken
together, these data lend to an intriguing suggestion
that suppression of NF-B activation in combination
with suppression of the B-raf/Mek/Erk/Stat3 pathway
m a yb eau s e f u ls t r a t e g yi nt h es u p p r e s s i o no fc a n c e r
progression. Many downstream signaling effectors
involved in malignancy are regulated by both Stat3 and
NF-B, such that targeting both of these signaling path-
ways at once by combining ATRA + AUR, may produce
a synergistic tumor suppressive effect. New evidence is
also helping to decipher the connections between NF-
B and STAT3. In 2007, Yang and associates discovered
that unphosphorylated STAT3 competes with IKB for
binding to unphosphorylated NF-B. This is turn results
in nuclear localization of this complex, leading to activa-
tion of NF-B regulated genes [39]. Most recently, Lee
a n dc o - w o r k e r sd e m o n s t r a t e dt h a tS T A T 3i m p a i r s
nuclear export of NF-B via activation of RelA acetyla-
tion [40]. Thus it appears that STAT3 may enhance the
effects of NF-B through multiple mechanisms.
The combinatorial effects of ATRA and AUR were
encouraging. AUR is known to activate Nrf2/ARE and
induces carcinogen and oxidant-detoxifying enzymes.
However, recently, a “dark side” of Nrf2 has been sug-
gested: that Nrf2 is upregulated in cancer (particularly
lung cancer) and provides cancer cells with protection
against the hostile tumor microenvironment [41]. In
fact, shRNA against Nrf2 in lung cancer cells attenuated
their growth in mouse xenografts compared to vector
control treated cells [42]. It is argued that chemopreven-
tive agents that increase Nrf2 activity may produce che-
moresistance to therapy [43]. However, Wang and
colleagues demonstrated that ATRA reduced binding of
Nrf2 to the ARE enhancer [42]. ATRA has been reputed
to possess pro-oxidant activities at therapeutic concen-
trations. If it suppresses Nrf2 activation it may render
cells more susceptible to oxidative stress. In fact, Tan
and colleagues confirmed that ATRA activates the Nrf2/
ARE transcription pathway [44]. Although beyond the
scope of the present study, it appears that perhaps
ATRA behaves in combination with AUR as a partial
agonist: that is, ATRA has a mild effect on activating
Nrf2 by itself, but is milder than AUR, and in combina-
tion, may mitigate the effects of AUR, leading to an
intermediate effect on Nrf2/ARE. Considering the
potentially controversial role of Nrf2/ARE in carcino-
genesis, we believe that the combination of ATRA with
AUR for cancer therapy is even more enticing, because
both agents were shown to be more effective at suppres-
sing tumor growth in combination, despite the appar-
ently intermediate effect on Nrf2/ARE.
Conclusions
In conclusion, we report that the combination of two
different phytochemicals, ACA and AUR in the diet,
enhanced the chemoprotective effect of ATRA against
human skin cancer cell growth in a xenograft model. In
particular, AUR appeared to be synergistic with the
effects of ATRA, whereas ACA appeared to prolong the
tumor suppressive effects of ATRA. We believe these
mechanisms to be related to the suppression of at least
two pathways, Stat3 and NF-B. Future studies may be
warranted to capitalize on using these combinations to
target multiple oncogenic pathways to enhance efficacy
and lower potential off-target effects.
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Additional file 1: Supplemental Table S1. 2 × 2 Factorial design for
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for ACA ± ATRA xenograft study. Supplemental Table S3. Body weight
(BW) statistics for ACA ± ATRA xenograft study. Supplemental Table S4:
Tumor volume (TV) as a function of ATRA dose: statistics for ACA ± ATRA
xenograft study. Supplemental Table S5: Body weight (BW) statistics for
ACA ± ATRA xenograft study as a function of ATRA dose. Supplemental
Table S6: Trend effect of ATRA dose in presence or absence of ACA on
tumor volume (TV). Supplemental Table S7: Tumor volume (TV) statistics
for AUR ± ATRA study. Supplemental Table S8: Body weight (BW) data
for AUR ± ATRA study.
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